MEI Pharma (LTS:0JW9) Preferred Dividends : $0.00 Mil (TTM As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is MEI Pharma Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. MEI Pharma's preferred dividends for the three months ended in Mar. 2025 was $0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil.

MEI Pharma Preferred Dividends Historical Data

The historical data trend for MEI Pharma's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MEI Pharma Preferred Dividends Chart

MEI Pharma Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Preferred Dividends

Get a 7-Day Free Trial

MEI Pharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Preferred Dividends	Get a 7-Day Free Trial															-	-	-	-	-

MEI Pharma Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

MEI Pharma (LTS:0JW9) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

MEI Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MEI Pharma Inc (LTS:0JW9) » Definitions » Preferred Dividends

Comparable Companies

Traded in Other Exchanges

MEIP:USA

Address

9920 Pacific Heights Blvd, Suite 150, San Diego, CA, USA, 92121

Website

https://www.meipharma.com

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

MEI Pharma Headlines

No Headlines